anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
High mobility group protein AT-hook 1 (HMGA1), an architectural transcription factor, has previously been reportedto play an essential role in architectural remodeling processes. However, its effects on cardiovascular diseases, particularly sepsis-induced cardiomyopathy, have remained unclear. The study aimed to investigate the role of HMGA1 in lipopolysaccharide-induced cardiomyopathy. Mice subjected to lipopolysaccharide for 12 h resulted in cardiac dysfunction. We used an adeno-associated virus 9 delivery system to achieve cardiac-specific expression of the HMGA1 gene in the mice. H9c2 cardiomyocytes were infected with Ad-HMGA1 to overexpress HMGA1 or transfected with si-HMGA1 to knock down HMGA1. Echocardiography was applied to measure cardiac function. RT-PCR was used to detect the transcriptional level of inflammatory cytokines. CD45 and CD68 immunohistochemical staining were used to detect inflammatory cell infiltration and TUNEL staining to evaluate the cardiomyocyte apoptosis, MitoSox was used to detect mitochondrial reactive oxygen species, JC-1 was used todetect Mitochondrial membrane potential. Our findings revealed that the overexpression of HMGA1 exacerbated myocardial inflammation and apoptosis in response to lipopolysaccharide treatment. Additionally, we also observed that H9c2 cardiomyocytes with HMGA1 overexpression exhibited enhanced inflammation and apoptosis upon stimulation with lipopolysaccharide for 12 h. Conversely, HMGA1 knockdown in H9c2 cardiomyocytes attenuated lipopolysaccharide-induced cardiomyocyte inflammation and apoptosis. Further investigations into the molecular mechanisms underlying these effects showed that HMGA1 promoted lipopolysaccharide-induced mitochondrial-dependent cardiomyocyte apoptosis. The study reveals that HMGA1 worsens myocardial inflammation and apoptosis in response to lipopolysaccharide treatment. Mechanically, HMGA1 exerts its effects by regulating the mitochondria-dependent apoptotic pathway.
A method is disclosed for the treatment of hepadnavirus infection in animals. Animals infected with duck hepatitis B virus may be treated with the 2 min ,3 min -dideoxynucleoside of adenine, guanine, hypoxanthine, 2,6-diaminopurine or various analogs of substituted purines. Several purine 2 min ,3 min -dideoxynucleosides inhibit duck hepatitis B virus in hepatocyte culture >99% at 1  mu g/ml. Potent in vivo efficacy of the 2,6-diaminopurine 2 min ,3 min -dideoxynucleoside for clearance of duck hepatitis B virus from the sera of Pekin ducks is demonstrated. The selective effect on hepadnavirus replication by the purine 2 min ,3 min -dideoxynucleosides is based on the discovery of an unexpected sensitivity of hepadnavirus to purine 2 min ,3 min -dideoxynucleoside analogs. These compounds present a new antiviral therapy of acute or persistent hepadnavirus infections.
The invention discloses a preparation method of ginseng and pilose antler foundation-strengthening decoction, which comprises a decoction prescription, a pill prescription, a wine prescription and a moxibustion prescription, wherein the four prescriptions are prepared by the following steps: the decoction prescription is as follows: 6g of ginseng, 6g of pilose antler, 25g of prepared rehmannia root (25 g of dried rehmannia root for patients with liver-kidney yin deficiency), 10g of dwarf lilyturf tuber (10 g of asparagus for patients with liver-kidney yin deficiency), 30g of astragalus root, 6g of Chinese angelica, 15g of epimedium, 10g of curculigo orchioides and 15g of dodder, and six doses are decocted for one hour every day to obtain 150 milliliters of half bowl. The middle disease can be stopped immediately, so it should not be taken for a long time. 6g of ginseng is soaked for one hour by adding 100 ml of boiled water into a warm cup, 6g of pilose antler is pulverized, and half of each powder is poured into a bowl and mixed with the decoction for taking. Decocting with water twice, half an hour after breakfast and supper. Decocting with water twice half an hour after breakfast and supper, taking six doses for one day, and continuously taking 24 doses, wherein one month is a treatment course. The invention can strengthen the body and the constitution of old male patients by matching the decoction prescription, the pill prescription, the wine prescription and the moxibustion prescription, enhance the accuracy of the medicine property among the medicinal materials, enhance the sexual function capability of old male patients, solve the problems that most prescriptions are not used for treating symptoms and root causes, are not accurate and appropriate in medicine compatibility and cannot have good curative effect on the sexual function of genitals, and enhance the life interest and feelings among couples.
PROBLEM TO BE SOLVED: To obtain the subject medicine capable of suppressing differentiation of keratinized cells in corneal epithelial cells, by including 1 α,24- dihydroxyvitamin D3 as an active ingredient. SOLUTION: This medicine is obtained by including 1 α,24-dihydroxyvitamin D3 , particularly preferably 1 α,24(R)-dihydroxyvitamin D3 , as an active ingredient. 1 α,24-Dihydroxyvitamin D3 has an effect to suppress differentiation of keratinized cells in corneal epithelial cells by suppressing expression of transglutaminase I in the corneal epithelial cells. The medicine is prepared, preferably as an ophthalmic solution, if necessary, by formulating commonly used additive(s). The ophthalmic solution is administered as a 0.00001-1% (w/v) solution once or several times a day. This medicine as an oral agent is administered at a rate of 0.1-5,000 mg/d in one to several portions.
Biceps tenodesis is a commonly performed procedure in shoulder surgery. In many cases, it is performed in conjunction with a rotator cuff repair. Currently, biceps tenodesis is performed in many different ways depending on surgeon preference. First, the location of the tenodesis can vary, as surgeons may prefer a suprapectoral or subpectoral tenodesis location. In addition, the tenodesis fixation technique can also vary, as surgeons have the option to use a screw or suture anchor to perform the tenodesis. There have been numerous studies comparing these various techniques, including suprapectoral versus subpectoral techniques and screw versus suture anchor techniques. None of these studies have been conclusive, and there continues to be controversy as to the best technique.

The current study will compare two techniques of subpectoral biceps tenodesis. Specifically, we will compare tenodesis using a suture anchor versus a technique where the tendon is simply sutured to the pectoralis major tendon. The latter technique has been previously described and published.
Compositions and methods are provided for the modulation of expression of the gene encoding β-amyloid in both the normal and mutant forms. Oligonucleotides are provided which are specifically hybridizable with RNA or DNA deriving from the β-amyloid precursor (βAPP) gene encoding β-amyloid, having nucleotide units sufficient in identity and number to effect such specific hybridization. Oligonucleotides specifically hybridizable with a translation initiation site or with the codon-717 mutation of βAPP are provided. Such oligonucleotides can be used for diagnostics as well as for research purposes. Methods are also disclosed for modulating β-amyloid expression in cells and tissues using the oligonucleotides provided, and for specific modulation of expression of the mutant βAPP gene. Methods for diagnosis, detection and treatment of conditions arising from the mutation of the βAPP gene are also disclosed.
PURPOSE:To obtain a colchicine-containing pharmaceutical for external use, useful as a remedy for gout, etc., and having enhanced percutaneous absorptivity and retentiveness by compounding colchicine and crotamiton. CONSTITUTION:A pharmaceutical obtained by blending colchicine and crotamiton with other ingredients. The above-mentioned pharmaceutical can be used in a dosage form of ointment, gel. cream, solution, cataplasma, etc. The colchicine is preferably blended in an amount of 0.01-2wt.% and the crotamiton is blended in an amount of 0.01-20wt.% in the pharmaceutical for external use. A normal base and blending ingredients, e.g. ointment base, gel, cream, lanolin and hardened oil, as necessary, are contained in the aforementioned pharmaceutical according to the dosage form.
Hypoxic-ischemic encephalopathy (HIE) is a form of newborn brain injury resulting from a lack of oxygen or blood flow to the brain. Over 85 percent of infants with HIE now survive to discharge from the Neonatal Intensive Care Unit (NICU). Therapeutic hypothermia, now standard of care for HIE, improves survival, but does not decrease the incidence of moderate-severe disability or cerebral palsy. Therefore, infants with HIE may benefit from close developmental surveillance and a sensorimotor intervention that may induce positive neuroplasticity and optimize developmental outcomes. In addition, parents of infants with HIE may benefit from anticipatory guidance to promote global development and extensive education on how to monitor their infant for neurological signs and developmental delays that would warrant further medical and therapeutic assessments and services.

The purpose of this study is to evaluate the feasibility and begin to evaluate the effect of a sensorimotor intervention (SMI) provided in the first 6 months of life. Twenty infants with moderate or severe HIE will be recruited and randomized into one of two groups: 1) standard care, and 2) standard care plus SMI. Infants in the SMI group will receive 2 intervention sessions in the NICU and 8 sessions in the home from 1 week to 6 months post discharge. The SMI will focus on supporting parents' ability to enhance motor-based problem solving and global development during the transition from NICU to home. Through this combined parent and therapist support intervention, the parents are empowered to provide their infants daily opportunities for sensorimotor play, increasing the likelihood of developmental change.

Outcomes will be measured at baseline, NICU discharge, and at 3 months and 6 months of age. Feasibility of enrolling, implementing the interventions, and completing the measurement model will be assessed. Secondary outcomes will include standardized assessments of motor and cognitive development of the infants and standardized assessments of confidence and stress of the parents. In addition, baseline neuroimaging data and the results of tests to detect cerebral palsy at 3 and 6 months of age will be used to characterize the participants and will be analyzed as potential moderators of treatment effects in future studies.
BACKGROUND & AIMS: Dysbiosis of the gut microbiota is considered a key contributor to inflammatory bowel disease (IBD) etiology. Here, we investigated potential associations between microbiota composition and the outcomes to biological therapies.
METHODS: The study prospectively recruited 296 patients with active IBD (203 with Crohn's disease, 93 with ulcerative colitis) initiating biological therapy. Quantitative microbiome profiles of pretreatment and posttreatment fecal samples were obtained combining flow cytometry with 16S amplicon sequencing. Therapeutic response was assessed by endoscopy, patient-reported outcomes, and changes in fecal calprotectin. The effect of therapy on microbiome variation was evaluated using constrained ordination methods. Prediction of therapy outcome was performed using logistic regression with 5-fold cross-validation.
RESULTS: At baseline, 65.9% of patients carried the dysbiotic Bacteroides2 (Bact2) enterotype, with a significantly higher prevalence among patients with ileal involvement (76.8%). Microbiome variation was associated with the choice of biological therapy rather than with therapeutic outcome. Only anti-tumor necrosis factor-α treatment resulted in a microbiome shift away from Bact2, concomitant with an increase in microbial load and butyrogen abundances and a decrease in potentially opportunistic Veillonella. Remission rates for patients hosting Bact2 at baseline were significantly higher with anti-tumor necrosis factor-α than with vedolizumab (65.1% vs 35.2%). A prediction model, based on anthropometrics and clinical data, stool features (microbial load, moisture, and calprotectin), and Bact2 detection predicted treatment outcome with 73.9% accuracy for specific biological therapies.
CONCLUSION: Fecal characterization based on microbial load, moisture content, calprotectin concentration, and enterotyping may aid in the therapeutic choice of biological therapy in IBD.
The invention relates to the use of derivatives of F-type prostaglandins as ocular hypotensives. The compounds used in accordance with the invention are represented by formula (I), wherein wavy line attachments indicate either the alpha (.alpha.) or beta (.beta.) configuration; hatched segments indicate .alpha. configuration; the solid triangle is used to indicate .beta. configuration; dashed bonds represent a double bond, or a single bond; R is a substituted heteroaryl radical having at least two pendant substituents selected from the group consisting of C1 to C6 alkyl; halogen; trifluoromethyl; COR1; COCF3; SO2NR1; NO2 and CN or at least one cyano group; R1 is hydrogen or a lower alkyl radical having up to six carbon atoms, X is selected from the group consisting of -OR1 and -N(R1)2; Y is = O or represents 2 hydrogen radicals and the 9, 11 or 15 lower alkyl esters thereof; provided, however, when said heteroaryl radical is a dichlorothienyl radical, the compound is not a 1-carboxylic acid or amide thereof. Certain of the compounds represented by Formula (I) are novel and comprise another aspect of the present invention.
The present invention relates to a skin adhesive type body patch equipped with a negative ion generation material and, more specifically, to a skin adhesive type body patch equipped with a negative ion generation material for preventing muscle pain, further muscle rupture by supplying negative ions to a corresponding region in order to remove active oxygen that causes the muscle pain. The present invention relates to a means for supplying negative ions through the skin using a negative ion generation material like tourmaline. According to an embodiment, a tourmaline binder of a set shape is installed on the surface of an air-permeable sheet at regular intervals to be formed and stacked in 1 mm or so and the sheet is cut in a set shape to be installed in the center of a patch portion. The tourmaline generates negative ions by reacting with sweat on the skin, and the negative ions penetrate into muscle fibers, where active oxygen is generated, through the skin to remove the active oxygen. In order to maximize such a function, making the negative ion generation material come in completely close contact with the skin is important above all things. In the convention method, the structure is difficult to maximize reactivity with sweat and permeability through the skin because of not being in close contact with the skin. In a patch-type method for being in close contact with the skin, the structure has a very low negative ion permeability effect because of using miscellaneous components besides the tourmaline. In order to solve the problem, the present invention proposes a skin adhesive type body patch equipped with a binder made only of the negative ion generation material like tourmaline.
FIELD: cosmetics. SUBSTANCE: mask includes mixture of fine-dispersive powder-like sorbent, bacteriostatic agent, flavor, and cosmetic organic water-soluble additive with boiling point above 100 C. Fine-dispersive powder-like sorbent is preliminarily dehydrated down to residual moisture content of not over 10-15%. Proportioning of components is as follows, mas.%: bacteriostatic agent 0.5-10.0, flavor 0.01-01, cosmetic organic water-soluble additive with boiling point above 100% 25.0-50.0, fine-dispersive powder-like sorbent - the balance. Used in function of sorbent are particles of silica gel or of silica gel and starch, or kaolin, or kaolin and starch, or zeolite, or zeolite and starch, or bentonite, or bentonite and starch, or aluminium dioxide, or aluminium dioxide and starch or synthetic organic ion exchanger, or synthetic organic ion exchanger and starch with dimension of 1-50 mcm. Used in function of cosmetic organic water-soluble additive with boiling point over 100 C is glycerin, or propylene glycol, or hexylene glycol. Used in function of bacteriostatic agent are such biocidic substances of vegetative origin as extract of bird cherry leaves, or extract of birch leaves, or extract of birch and bird cherry leaves, or silver fir oil, or extract of bird cherry leaves and silver fir oil, or extract of calendula flowers, or extracts of calendula flowers, leaves of birch and bird cherry. Aforesaid skin care mask ensures effective removal of moisture from surface and intercellular space with simultaneous sorbing cleaning of skin. EFFECT: higher efficiency. 4 cl, 14 ex
Post-traumatic stress disorder (PTSD) is a disorder that forms in response to a traumatic event. The symptoms of PTSD, such as hyper-arousal and re-experiencing the traumatic event, are common in all people who have recently experienced a trauma, but those who develop PTSD continue to have these symptoms more than a month after the trauma. Some researchers believe that developing PTSD is the result of a failure to adequately recover from the trauma. This study will determine whether providing a common form of treatment for PTSD, prolonged exposure (PE) therapy, to people who have recently experienced trauma will prevent them from developing PTSD. The study will also seek to identify predictive markers, such as hormone levels and genes, for developing PTSD.

Participation in this study will last 3 months. Participants will first undergo an evaluation session that will include an interview, questionnaires, and a medical chart review for blood pressure and heart rate measurements taken after their trauma. They will then be randomly assigned to receive either PE therapy or assessments only. Participants receiving PE therapy will complete three weekly treatment sessions, with the first occurring immediately after the evaluation session. Treatment will involve reviewing memories of a recent trauma out loud with a therapist and audio-recording these discussions for review at home. All participants will undergo assessments 1 and 3 months after the initial evaluation session. The 1-month assessment will involve an interview and questionnaires similar to the evaluation session, and the 3-month session will involve only a brief phone interview. Some participants will also be asked to complete an optional part of the study in which they provide two saliva samples to researchers: one to measure stress hormones and one to test for genetic bases of trauma response.
BACKGROUND: Whether or not to progress from a pilot study to a definitive trial is often guided by pre-specified quantitative progression criteria with three possible outcomes. Although the choice of these progression criteria will help to determine the statistical properties of the pilot trial, there is a lack of research examining how they, or the pilot sample size, should be determined.
METHODS: We review three-outcome trial designs originally proposed in the phase II oncology setting and extend these to the case of external pilots, proposing a unified framework based on univariate hypothesis tests and the control of frequentist error rates. We apply this framework to an example and compare against a simple two-outcome alternative.
RESULTS: We find that three-outcome designs can be used in the pilot setting, although they are not generally more efficient than simpler two-outcome alternatives. We show that three-outcome designs can help allow for other sources of information or other stakeholders to feed into progression decisions in the event of a borderline result, but this will come at the cost of a larger pilot sample size than the two-outcome case. We also show that three-outcome designs can be used to allow adjustments to be made to the intervention or trial design before commencing the definitive trial, providing the effect of the adjustment can be accurately predicted at the pilot design stage. An R package, tout, is provided to optimise progression criteria and pilot sample size.
CONCLUSIONS: The proposed three-outcome framework provides a way to optimise pilot trial progression criteria and sample size in a way that leads to desired operating characteristics. It can be applied whether or not an adjustment following the pilot trial is anticipated, but will generally lead to larger sample size requirements than simpler two-outcome alternatives.
Fatty material causing a tick to relax its biting pressure before easy removal is held in a container bowl (21) normally attached to an adhesive extension (22) for holding the dressing against the skin. When not reqd. for appication, the fatty material is totally enclosed by a cover (22) pref. of self-adhesive material. The extension (22) and bowl container may be made integrally or as separate elements. Bowl shape is pref. hemispherical. USE/ADVANTAGE - For travellers, walkers, etc.. An easy method of providing more effective tick removal than the known use of pincers, which can still end in infection.
The Ferrlecit iron complex is not dialyzable. 

No data is available regarding overdose of Ferrlecit in humans. Excessive dosages of Ferrlecit may lead to accumulation of iron in storage sites potentially leading to hemosiderosis. Do not administer Ferrlecit to patients with iron overload [see Warnings and Precautions (5.3)].

Individual doses exceeding 125 mg may be associated with a higher incidence and/or severity of adverse events [see Adverse Reactions (6.2)]. 

Ferrlecit at elemental iron doses of 125 mg/kg, 78.8 mg/kg, 62.5 mg/kg and 250 mg/kg caused deaths in mice, rats, rabbits, and dogs respectively. The major symptoms of acute toxicity were decreased activity, staggering, ataxia, increases in the respiratory rate, tremor, and convulsions.
All other patients enrolled in 20030165 who expired or experienced disease progression (PD). Patients will be followed annually for survival.
Endometriosis is a chronic inflammatory disorder characterized by the abnormal growth of endometrial-like tissue outside the uterine cavity, affecting 10-15% of women of reproductive age. Pain is the most common symptom. Treatment options include surgery, which has limited effectiveness and high recurrence rates, and pharmacotherapy. Hormonal therapies, commonly used for symptom management, can have side effects and contraceptive outcomes, contributing to the infertility associated with endometriosis, with pain and lesions often reappearing after treatment cessation. Among its etiological factors, immunological and inflammatory dysregulation plays a significant role, representing an interesting target for developing new therapeutic strategies. This review critically analyzes recent studies to provide an updated synthesis of ongoing research into potential new pharmacotherapies focusing on lesion progression, pain relief, and improving quality of life. Immunotherapy, natural anti-inflammatory and antioxidant compounds and drug repurposing show promise in addressing the limitations of current treatments by targeting immunological factors, potentially offering non-invasive solutions for managing pain and infertility in endometriosis. Promising results have been obtained from in vitro and animal model studies, but clinical trials are still limited. More effort is needed to translate these findings into clinical practice to effectively reduce disease progression, alleviate pain symptoms and preserve the reproductive capacity, improving patients' overall wellbeing.